PLGA Biotin Capped is a professional category of biotin-terminated biodegradable PLGA (poly(lactide-co-glycolide)) copolymers, widely utilized for targeted drug delivery, streptavidin-biotin bioconjugation, nanoparticle/microsphere formulation, surface functional modification, and high-end biomedical material research. Differing from conventional carboxyl-terminated and ester-terminated PLGA, this series is precisely end-capped with active biotin groups, enabling highly specific, high-affinity, and stable non-covalent binding with avidin and streptavidin proteins, which is the core material for active targeting and biological coupling in modern pharmaceutical and biomedicine studies.
The PLGA Biotin Capped product series covers a complete gradient of molecular weights including MW 2K, MW 5K, MW 10K, MW 20K, and MW 40K, fully matching different degradation cycles from rapid release, sustained release to multi-year ultra-long slow release. Meanwhile, the series supports mainstream lactide-glycolide ratios of 50:50, 75:25, 85:15, as well as fully customized ratio services. Researchers can accurately adjust polymer solubility, hydrophobicity, mechanical strength, structural stability, and in vivo degradation kinetics by selecting different molecular weights and monomer ratios, realizing customized formulation design for diverse biomedical scenarios.
All polymers in the PLGA Biotin Capped series possess excellent biocompatibility, biosafety, and complete biodegradability. The materials can be naturally hydrolyzed into lactic acid and glycolic acid in physiological environments without toxic residue or inflammatory irritation. With stable terminal biotin activity and reliable polymer structural performance, this series is suitable for in vitro bioconjugation experiments, targeted nanoparticle preparation, sustained-release drug carrier construction, biological probe labeling, and long-term implantable biomaterial development. It is a standardized and versatile functional polymer platform for avidin-biotin based biomedical engineering and targeted pharmaceutical research.
Product Series Features
Stable Biotin End Functionalization: Uniform terminal biotin capping ensures high bioconjugation efficiency and stable streptavidin binding activity, supporting repeatable and reliable biological modification.
Complete Molecular Weight Gradient: Covers low, medium, high, and ultra-high molecular weight specifications (2K–40K) to meet rapid, medium, and ultra-long degradation and release requirements.
Multiple & Customizable PLGA Ratios: Optional 50:50, 75:25, 85:15 and custom ratios for precise regulation of material hydrophilicity and degradation cycle.
High Biocompatibility & Biodegradability: In vivo safe and fully degradable, compliant with mainstream biomedical and pharmaceutical research standards.
Wide Application Compatibility: Adaptable for nanoparticle formulation, microsphere preparation, drug sustained release, antibody/probe conjugation, and implantable material fabrication.
General Applications
Targeted drug delivery systems, biotin-streptavidin bioconjugation, polymeric particle synthesis and surface modification, biomedical probe labeling, functional polymer derivation, and degradable biomaterial scaffold research.
General Storage & Handling
Store at -20 °C in sealed, dry, moisture-proof conditions. Avoid repeated freeze-thaw cycles, high temperature, and moisture exposure to prevent polymer hydrolysis and biotin activity attenuation. Long-term inert gas sealing is recommended for maximum shelf-life stability.
PLGA Biotin Capped
PLGA Biotin Capped is a full-series biotin-terminated biodegradable PLGA copolymer collection with complete MW gradients (2K–40K) and multiple lactide-glycolide ratios, designed for high-affinity biotin-streptavidin conjugation, targeted drug delivery, and functional biomedical material research.